- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03922581
Primary-Care Based Mindfulness Intervention
Primary-Care Based Mindfulness Intervention for Chronically Traumatized Individuals
Study Overview
Status
Intervention / Treatment
Detailed Description
There is significant public health burden of chronic trauma exposure in low income, predominantly ethnic minority, urban communities, which is reflected in the extraordinarily high levels of trauma-related psychiatric disorders, particularly PTSD and MDD. Despite this, limited access to behavioral health treatment and significant barriers to treatment engagement and success remain and integrating mind-body approaches in medical settings could be a critical next step in treating chronically traumatized individuals in these urban settings. This study will utilize a randomized controlled trial design along with a multi-method assessment approach to ascertain the feasibility, acceptability, and preliminary mechanisms of action and outcomes of mindfulness-based cognitive therapy versus wait-list control in 80 African Americans with chronic trauma exposure and comorbid PTSD and MDD symptoms.
Participants will be randomized to an 8-session (90 minutes each) group intervention or wait-list control. The researchers will examine the retention and follow-up rates, participants' report of acceptability and interest in the intervention, and examine barriers to treatment engagement through self-report measures and exit interviews. This study will also investigate preliminary mechanisms of action and outcomes of the mindfulness intervention in targeting emotion regulation and autonomic processes by measuring self-report of emotion dysregulation using the Difficulties in Emotion Regulation Scale and autonomic arousal to trauma cues using eSense technology to assess skin conductance during administration of Standardized Trauma Interview. Latent growth modeling will assess relative changes in emotion dysregulation and autonomic function over time through intervention and 1 month follow-up.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Grady Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ability to provide informed consent
- willingness to participate in study
- self-identity as African American
- history of childhood and/or adult trauma exposure (3 total criterion A traumas)
- positive PTSD screen (PC-PTSD ≥ 3)
- positive MDD screen (PHQ-9 ≥ 10)
Exclusion Criteria:
- presence of intellectual disability, bipolar, or psychotic disorder
- presence of current substance use disorder (past 1 month; see cut off scores in psychological measures below)
- active suicidality
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mindfulness-Based Cognitive Therapy
Participants randomized to this study arm will receive Mindfulness-Based Cognitive Therapy (MBCT) for 8 weeks.
|
The intervention consists of MBCT for the prevention of depression relapse with adaptations for discussing trauma and PTSD.
Participants attend eight, weekly 90-minute group sessions involving skills training and in-class practice.
Participants will return one month after the intervention has ended for a follow-up assessment.
|
No Intervention: Wait-list Control Group
Participants randomized to the wait-list control study arm will be administered the study assessments while not receiving active treatment.
Participants will be given the opportunity to participate in the MBCT intervention following completion of the study assessments.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Retention rate
Time Frame: Baseline through Follow-up (1 month after the end of the 8-week intervention)
|
Retention rates will be assessed using session attendance.
Previous mindfulness-based stress reduction (MBSR) interventions among low-income minority populations have yielded completion rates of 53-80%.
Based on 80% completion rates of MBSR in primary care and 75% completion rates of MBCT both in combat vet samples and the anticipated improved accessibility through primary care, it is expected that subjects in the intervention group will evidence at least 75% retention and follow-up rates.
|
Baseline through Follow-up (1 month after the end of the 8-week intervention)
|
Client Satisfaction Questionnaire (CSQ) Score
Time Frame: Week 8
|
Feasibility and acceptability will be assessed using the Client Satisfaction Questionnaire (CSQ).
The CSQ is an 8-item questionnaire asking respondents to rate the quality of care they received on a scale from 1 to 4 where 1 = poor and 4 = excellent.
Total raw scores range from 8 to 24 where higher values indicate greater satisfaction.
|
Week 8
|
Perceived Barriers to Psychological Treatment (PBPT) Scale Score
Time Frame: Week 8
|
Barriers to treatment will be assessed using the Perceived Barriers to Psychological Treatment (PBPT) scale.
The PBPT is a 25-item scale asking respondents about factors that interfere with attending weekly therapy.
Items are rated on a 5-point scale where 1 = impossible to attend and 5 = not a problem.
Total raw scores range from 25 to 125 where higher scores indicate low barriers regarding attending psychotherapy.
|
Week 8
|
Change in Difficulties in Emotion Regulation Scale (DERS) Score
Time Frame: Baseline, Weeks 3, 5, 7, 8, and Follow-up (1 month after the end of the intervention)
|
The Difficulties in Emotion Regulation Scale (DERS) is a 36-item instrument assessing emotion dysregulation and includes six subscales (non-acceptance of emotions, difficulty with goal-directed behavior in the presence of negative emotions, difficulty controlling impulses in the presence of negative emotions, lack of awareness of emotions, limited use of effective emotion regulation strategies, and lack of understanding of emotions).
Responses are scaled from 1 (almost never) to 5 (almost always).
Total raw scores range from 36 to 180; certain items are reverse scored so that higher scores indicate increased difficulty with emotion regulation.
|
Baseline, Weeks 3, 5, 7, 8, and Follow-up (1 month after the end of the intervention)
|
Post-group Follow-up Questionnaire
Time Frame: Week 8
|
Participants randomized to the MBCT intervention will complete an open-ended, follow-up questionnaire designed to assess feelings and changes experienced from participation in the intervention.
The 10 questions include "how did you feel about the group?" and "what barriers came up for you in participating in the group?".
Responses are in text form rather than on a pre-set scale.
|
Week 8
|
Change in skin conductance
Time Frame: Baseline, Week 8, Follow-up (3 months after the end of the intervention)
|
Skin conductance (SC) response will be measured using a mobile SC device, eSense (Mindfield Biosystems).
Continuous recording of SC is measured with electrodes on hands and data is transmitted through the eSense app.
Using the PhenX Toolkit protocol, a two minute baseline measure of SC will be obtained and then SC levels will be measured during administration of the Standardized Trauma Interview immediately following to determine physiological reactivity to trauma stimuli.
SC response is calculated by subtracting SC level at the end of baseline recording (average of last 30 seconds) from the maximum SC level value during the trauma interview.
|
Baseline, Week 8, Follow-up (3 months after the end of the intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Primary Care PTSD Screen (PC-PTSD) Determination
Time Frame: Baseline, Week 8, Follow-up (1 month after the end of the intervention)
|
The Primary Care PTSD Screen (PC-PTSD) is a 4-item screen designed for use in primary care will assess for presence of PTSD symptoms and serve as PTSD screener.
Respondents answer "yes" or "no" to each question and an individual is considered to have PTSD if they respond with "yes" to at least 3 of the 4 questions.
|
Baseline, Week 8, Follow-up (1 month after the end of the intervention)
|
Change in Patient Health Questionnaire-9 (PHQ-9) Score
Time Frame: Baseline, Week 8, Follow-up (1 month after the end of the intervention)
|
The Patient Health Questionnaire-9 (PHQ-9) will assess for presence of depressive symptoms and serve as MDD screening tool.
The PHQ-9 is a 9-item tool that asks respondents to indicate how frequently they have felt symptoms of depression on a scale of 0 to 3 where 0 = not at all and 3 = nearly every day.
Total scores range from 0 to 27, where higher scores indicate worse depression.
|
Baseline, Week 8, Follow-up (1 month after the end of the intervention)
|
Change in PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 (PCL-5) Score
Time Frame: Baseline, Week 8
|
The PCL-5 is a 20-item questionnaire asking respondents to report how much they have been bothered by problems in the past month on a scale of 0 (not at all) to 4 (extremely).
Total scores range from 0 to 80 where higher scores indicate increased difficulty with responses to stressful experiences.
|
Baseline, Week 8
|
Change in Beck Depression Inventory-II (BDI-II) Score
Time Frame: Baseline, Week 8
|
The BDI-II is a 21-item instrument asking respondents to indicate how much they are bothered by negative feelings.
Responses are on a scale of 0 to 3 where 0 = the problematic feeling is not present and 3 = the feeling is very strong.
Total scores range from 0 to 63, where high scores indicate worse problems with negative feelings.
|
Baseline, Week 8
|
Change in Clinician Administered PTSD Scale PTSD Determination
Time Frame: Baseline, Week 8
|
The Clinician Administered PTSD Scale is a semi-structured interview used for diagnosing PTSD.
The number of participants diagnosed with PTSD pre- and post-intervention will be compared between study arms.
|
Baseline, Week 8
|
Change in Mini International Neuropsychiatric Interview (MINI) MDD Determination
Time Frame: Baseline, Week 8
|
The Mini International Neuropsychiatric Interview (MINI) is a semi-structured interview used for diagnosing MDD.
The number of participants diagnosed with MDD pre- and post-intervention will be compared between study arms.
|
Baseline, Week 8
|
Change in Five Facet Mindfulness Questionnaire Score
Time Frame: Baseline, Week 8, Follow-up (1 month after the end of the intervention)
|
The Five Facet Mindfulness Questionnaire is a 39-item instrument assessing mindfulness, and includes five facets (observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience).
Participants respond to each item on a scale of 1 to 5 where 1 = the statement is never or very rarely true for them and 5 = the statement is very often or always true.
Total raw scores range from 39 to 195; certain items are reverse scored so that higher scores indicate increased mindfulness.
|
Baseline, Week 8, Follow-up (1 month after the end of the intervention)
|
Change in Self Compassion Scale, Short Form Score
Time Frame: Baseline, Week 8, Follow-up (1 month after the end of the intervention)
|
The Self Compassion Scale is a 12-item instrument assessing how respondents typically act towards themselves during difficult times.
Items are answered on a scale of 1 to 5 where 1 = almost never and 5 = almost always.
Total scores range from 12 to 60; certain items are reversed scored so that higher scores indicate increased self compassion.
|
Baseline, Week 8, Follow-up (1 month after the end of the intervention)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Abigail Lott, PhD, Emory University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00104519
- K23AT009713 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post Traumatic Stress Disorder
-
University of California, Los AngelesDefense Advanced Research Projects Agency; Defense Group, Inc.CompletedPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder, ChronicUnited States
-
University of California, Los AngelesRecruitingPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder in ChildrenUnited States
-
Weill Medical College of Cornell UniversityCompletedPost-traumatic Stress Disorder | Complex Post-Traumatic Stress DisorderUnited States
-
University of UtahEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPost-Traumatic Stress Disorder in Children | Post-Traumatic Stress Disorder in AdolescenceUnited States
-
University of ZurichCompletedPost Traumatic Stress Disorder (PTSD) | Complex Post-Traumatic Stress Disorder (CPTSD)Switzerland
-
University of NottinghamNottinghamshire Healthcare NHS Trust; Lincolnshire Partnership NHS Foundation...CompletedDomestic Violence | Trauma, Psychological | Post-Traumatic Stress Disorder in Children | Narrative Exposure Therapy | Post-Traumatic Stress Disorder in Adolescence | Post-Traumatic Stress Disorder ComplexUnited Kingdom
-
Praxis Precision MedicinesTerminatedStress Disorders, Post-Traumatic | Trauma and Stressor Related Disorders | Post Traumatic Stress Disorder | Stress Disorder | Post-traumatic Stress Disorder | Mental DisorderUnited States
-
Erkin Oğuz SARINot yet recruitingPost-Traumatic Stress DisorderTurkey
-
University Hospital, LilleNot yet recruiting
-
Steinn SteingrimssonRecruiting
Clinical Trials on Mindfulness-Based Cognitive Therapy
-
University of WarsawNot yet recruitingModerate Depressive Episode | Mild Depressive Episode
-
Oregon Health and Science UniversityTerminatedPostpartum Depression | Prenatal Stress | Maternal Psychological DistressUnited States
-
The University of QueenslandUniversity of Alabama at Birmingham; Rush University Medical Center; University...Completed
-
Oregon Health and Science UniversityCompletedPregnancy Related | Infant Development | Prenatal Stress | Functional Neuroimaging | Maternal Psychological DistressUnited States
-
University of WashingtonNational Multiple Sclerosis SocietyCompletedMultiple SclerosisUnited States
-
Vancouver Coastal HealthRecruitingSituational Erectile DysfunctionCanada
-
Massachusetts General HospitalMayo Clinic; University of Pennsylvania; University of South Florida; University... and other collaboratorsCompleted
-
University Medical Center GroningenUniversity of GroningenCompleted
-
University of California, Los AngelesCompletedMood Disorders | Bipolar Disorder | Parents | Prodromal Symptoms | Clinical High RiskUnited States
-
Qazvin University Of Medical SciencesUnknownInsomniaIran, Islamic Republic of